Interestingly, Arshad et al. (2015) found that in 10 patients with cirrhosis, DDAVP administration did not result in changes to high molecular weight VWF multimers, VWF:Ag, and VWF-dependent platelet adhesion, but did find similar increases in FVIII activity and VWF pro-peptides in patients with cirrhosis compared with patients with mild HA [84]. The gene discussed is VWF; the disease is Cirrhosis.